EE05662B1 - Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine - Google Patents

Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine

Info

Publication number
EE05662B1
EE05662B1 EEP200100549A EEP200100549A EE05662B1 EE 05662 B1 EE05662 B1 EE 05662B1 EE P200100549 A EEP200100549 A EE P200100549A EE P200100549 A EEP200100549 A EE P200100549A EE 05662 B1 EE05662 B1 EE 05662B1
Authority
EE
Estonia
Prior art keywords
composition
hiku
antagonist
sub
treating fibrosis
Prior art date
Application number
EEP200100549A
Other languages
English (en)
Estonian (et)
Inventor
Gotwals Philip
R. Lobb Roy
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200100549A publication Critical patent/EE200100549A/xx
Publication of EE05662B1 publication Critical patent/EE05662B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200100549A 1999-04-22 2000-04-21 Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine EE05662B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13084799P 1999-04-22 1999-04-22
US13721499P 1999-06-01 1999-06-01
PCT/US2000/010781 WO2000064474A1 (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Publications (2)

Publication Number Publication Date
EE200100549A EE200100549A (et) 2002-12-16
EE05662B1 true EE05662B1 (et) 2013-06-17

Family

ID=26828876

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100549A EE05662B1 (et) 1999-04-22 2000-04-21 Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine

Country Status (31)

Country Link
US (3) US6652856B2 (de)
EP (1) EP1173201B1 (de)
JP (3) JP5483515B2 (de)
KR (3) KR100837715B1 (de)
CN (3) CN1191860C (de)
AT (1) ATE298249T1 (de)
AU (1) AU783054B2 (de)
BG (2) BG65578B1 (de)
BR (1) BR0010669A (de)
CA (1) CA2370814C (de)
CY (1) CY1106046T1 (de)
CZ (1) CZ301636B6 (de)
DE (1) DE60020955T2 (de)
DK (1) DK1173201T3 (de)
EA (1) EA006681B1 (de)
EE (1) EE05662B1 (de)
ES (1) ES2243259T3 (de)
GE (1) GEP20063844B (de)
HK (1) HK1041452B (de)
HU (1) HU226383B1 (de)
IL (5) IL145898A0 (de)
IS (1) IS2259B (de)
MX (1) MXPA01010612A (de)
NO (1) NO330221B1 (de)
NZ (2) NZ515053A (de)
PL (1) PL198975B1 (de)
PT (1) PT1173201E (de)
RS (2) RS50086B (de)
SK (1) SK287328B6 (de)
TR (1) TR200200027T2 (de)
WO (1) WO2000064474A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL198975B1 (pl) * 1999-04-22 2008-08-29 Biogen Idec Inc Zastosowanie kompozycji zawierającej homolog przeciwciała, który jest antagonistą interakcji między integryną niosącą podjednostkę alfa 4 a jej ligandem
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
HK1043320A1 (zh) 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
ATE363271T1 (de) * 2000-03-17 2007-06-15 Avocet Polymer Technologies In Verfahren zur verbesserung der grösse und des aussehens einer wunde
JP2004512345A (ja) * 2000-11-02 2004-04-22 スミスクライン・ビーチャム・コーポレイション 受容体アンタゴニスト−脂質コンジュゲートおよびそれを含有するデリバリービヒクル
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
JP2007531697A (ja) * 2003-07-11 2007-11-08 プロ−ファーマシューティカルズ，インコーポレイティド 疎水性薬剤のデリバリーのための組成物と方法
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
JP5037134B2 (ja) * 2003-10-17 2012-09-26 レハブ アル−ジャマル 組織修復
EP1718146A2 (de) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von akne und candida
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
BRPI0712607A8 (pt) * 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
ES2700141T3 (es) * 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
CA2875200C (en) * 2012-03-28 2024-02-20 Hiroshima University Fibrosis suppression by inhibiting integrin alpha8beta1 function
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
US20210115122A1 (en) * 2018-02-23 2021-04-22 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent tgf-beta 1 antibodies and methods of use
KR20250093432A (ko) 2019-08-28 2025-06-24 추가이 세이야쿠 가부시키가이샤 종교차성 항잠재형 TGF-β1 항체 및 사용 방법
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
WO1993013798A1 (en) * 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ES2424292T3 (es) * 1994-01-25 2013-09-30 Biogen Idec Ma Inc. Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4
ES2151054T3 (es) * 1994-04-26 2000-12-16 Kanebo Ltd Farmaco para el tratamiento de la artritis reumatoide.
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0827742A1 (de) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
JPH10330268A (ja) * 1997-05-26 1998-12-15 Kureha Chem Ind Co Ltd ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤
EP0996460B1 (de) * 1997-08-08 2005-01-12 The Regents of the University of California Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
PL198975B1 (pl) * 1999-04-22 2008-08-29 Biogen Idec Inc Zastosowanie kompozycji zawierającej homolog przeciwciała, który jest antagonistą interakcji między integryną niosącą podjednostkę alfa 4 a jej ligandem
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑

Also Published As

Publication number Publication date
RS50086B (sr) 2009-01-22
EA006681B1 (ru) 2006-02-24
BG65578B1 (bg) 2009-01-30
TR200200027T2 (tr) 2002-07-22
BR0010669A (pt) 2002-02-19
ES2243259T3 (es) 2005-12-01
EA200101116A1 (ru) 2002-04-25
AU783054B2 (en) 2005-09-22
HK1041452B (en) 2005-10-14
SK287328B6 (sk) 2010-07-07
MXPA01010612A (es) 2003-09-04
DK1173201T3 (da) 2005-09-12
EP1173201B1 (de) 2005-06-22
HK1076379A1 (zh) 2006-01-20
RS20080471A (sr) 2010-12-31
KR100746522B1 (ko) 2007-08-07
DE60020955T2 (de) 2006-05-11
EE200100549A (et) 2002-12-16
HUP0201015A2 (hu) 2002-07-29
HK1041452A1 (en) 2002-07-12
CY1106046T1 (el) 2011-04-06
HU226383B1 (hu) 2008-10-28
US20040037827A1 (en) 2004-02-26
EP1173201A1 (de) 2002-01-23
JP2007182453A (ja) 2007-07-19
DE60020955D1 (de) 2005-07-28
US6652856B2 (en) 2003-11-25
PL351916A1 (en) 2003-06-30
CZ301636B6 (cs) 2010-05-12
PL198975B1 (pl) 2008-08-29
CN100360183C (zh) 2008-01-09
BG106118A (en) 2002-05-31
CN1356911A (zh) 2002-07-03
IS2259B (is) 2007-06-15
NO330221B1 (no) 2011-03-07
CA2370814C (en) 2010-07-06
IL206829A0 (en) 2010-12-30
HUP0201015A3 (en) 2004-12-28
CN1191860C (zh) 2005-03-09
IL206830A (en) 2013-06-27
GEP20063844B (en) 2006-06-12
US20050281818A1 (en) 2005-12-22
SK15202001A3 (sk) 2002-09-10
IL182908A0 (en) 2007-08-19
KR20070050979A (ko) 2007-05-16
IL145898A0 (en) 2002-07-25
YU74901A (sh) 2004-07-15
WO2000064474A8 (en) 2001-04-05
NO20015122D0 (no) 2001-10-19
IL145898A (en) 2007-07-24
KR20070102760A (ko) 2007-10-19
CZ20013754A3 (cs) 2002-07-17
KR20020000221A (ko) 2002-01-05
NO20015122L (no) 2001-12-21
CN1332714C (zh) 2007-08-22
CN1596979A (zh) 2005-03-23
CA2370814A1 (en) 2000-11-02
KR100837715B1 (ko) 2008-06-13
IL206829A (en) 2013-06-27
IL182908A (en) 2010-11-30
NZ515053A (en) 2004-02-27
CN1679935A (zh) 2005-10-12
JP2002542300A (ja) 2002-12-10
IL206830A0 (en) 2010-12-30
WO2000064474A1 (en) 2000-11-02
US20020182213A1 (en) 2002-12-05
ATE298249T1 (de) 2005-07-15
BG66149B1 (bg) 2011-08-31
JP5483515B2 (ja) 2014-05-07
NZ541431A (en) 2008-01-31
AU4480000A (en) 2000-11-10
IS6105A (is) 2001-10-11
JP2014065747A (ja) 2014-04-17
PT1173201E (pt) 2005-08-31
BG110115A (en) 2008-12-30

Similar Documents

Publication Publication Date Title
IL206830A0 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
ATE327004T1 (de) Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
LU93274I2 (fr) Elotuzumab
EA200401584A1 (ru) Способ содействия прекращению курения
EE04576B1 (et) Suposiit happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod, toimeaineühik ja selle valmistamismeetod ning preparaat
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
PT777482E (pt) Composicao de combinacao para utilizacao em doencas imunologicas
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
DE60101339D1 (de) Stimulierung des knochenwachstums mit peptidderivaten von thrombin
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
EE05235B1 (et) Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
EA200100041A1 (ru) Способ лечения
EP1666063A3 (de) Verfahren zur Behandlung von Fibrose unter Verwendung eines Antagonisten der Alpha-4 Untereinheit von Integrin

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20150421